Skip to content

    Ultragenyx Pharmaceutical (RARE) stock price & financials

    View RARE earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance14.9% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $139.49M
    $164.65M
    $139.00M
    $167.00M
    $159.93M
    +14.7%
    $207.07M
    +25.8%
    $136.00M
    -2.2%
    $214.00M
    +28.1%
    Strengthening
    Operating Profit
    -$131.99M
    -$122.31M
    -$143.00M
    -$108.00M
    -$170.89M
    -29.5%
    -$113.11M
    +7.5%
    -$169.00M
    -18.2%
    -$75.00M
    +30.6%
    Strengthening
    Net Profit
    -$133.52M
    -$133.20M
    -$151.00M
    -$115.00M
    -$180.41M
    -35.1%
    -$128.59M
    +3.5%
    -$185.00M
    -22.5%
    -$92.00M
    +20.0%
    Stable
    EPS
    $-1.40
    $-1.57
    $-1.17
    $-1.81
    -29.3%
    $-1.84
    -17.2%
    $-0.90
    +23.1%
    Stable
    Other Income
    Interest
    Depreciation
    Profit before Tax
    -$133.21M
    -$132.82M
    -$150.00M
    -$114.00M
    -$179.54M
    -34.8%
    -$127.46M
    +4.0%
    -$184.00M
    -22.7%
    -$91.00M
    +20.2%
    Stable
    MarginsOPM
    -94.6%
    -74.3%
    -102.9%
    -64.7%
    -106.8%
    -12.9%
    -54.6%
    +26.5%
    -124.3%
    -20.8%
    -35.0%
    +45.8%
    Strengthening
    Tax
    -0.2%
    -0.3%
    -0.7%
    -0.9%
    -0.5%
    -113.0%
    -0.9%
    -203.4%
    -0.5%
    +19.4%
    -1.1%
    -25.0%
    Weakening
    ReturnsROIC
    2.8%
    2.8%
    3.1%
    2.4%
    3.8%
    +35.1%
    2.7%
    -3.5%
    3.8%
    +22.5%
    1.9%
    -20.0%
    Stable

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$113.43M$433.58M$713.53M$307.58M$132.94M$214.00M$174.00M$421.00M$125.00M
    Short-Term Investments
    Total Current Assets$522.37M$851.02M$1.30B$856.60M$883.90M$732.18M$817.00M$951.00M$606.00M
    Net PP&E$20.05M$74.68M$114.04M$176.18M$285.73M$314.47M$292.00M$267.00M$235.00M
    Goodwill$44.41M$44.41M$44.41M$44.41M$44.41M$44.41M$44.00M$44.00M$44.00M
    Intangibles$129.22M$129.00M$131.11M$130.79M$160.10M$166.27M$178.00M$176.00M$172.00M
    Total Assets$719.56M$1.14B$1.76B$1.52B$1.55B$1.49B$1.50B$1.53B$1.26B
    LiabilitiesTotal Current Liabilities$74.72M$103.30M$189.61M$181.37M$261.21M$280.44M$344.00M$384.00M$351.00M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$29.76M$38.55M$30.49M$19.81M$30.57M$30.00M$24.00M
    Total Liabilities$110.65M$481.73M$605.18M$599.84M$1.19B$1.22B$1.24B$1.60B$1.55B
    EquityCommon Stock & APIC$51.0K$58.0K$67.0K$69.0K$70.0K$82.0K$0$0$0
    Retained Earnings-$1.03B-$1.43B-$1.62B-$2.07B-$2.78B-$3.39B-$3.96B-$4.53B-$4.81B
    Total Equity$608.91M$653.76M$1.15B$922.56M$352.00M$275.00M$255.00M-$80.00M-$291.00M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$290.57M-$345.38M-$132.22M-$338.69M-$380.46M-$475.00M-$414.00M-$466.00M-$485.00M
    Cash from Investing-$33.33M-$13.04M-$179.12M-$195.37M-$291.65M$168.00M-$18.00M$236.00M$40.00M
    Cash from Financing$336.85M$679.31M$600.27M$118.55M$501.21M$388.00M$399.00M$478.00M
    SummaryCapital Expenditure-$4.08M-$24.83M-$43.91M-$73.09M-$116.12M-$44.00M-$7.00M-$6.00M-$4.00M
    Free Cash Flow-$294.64M-$370.21M-$176.13M-$411.79M-$496.59M-$519.00M-$421.00M-$472.00M-$489.00M
    FCF Margin-572.2%-357.0%-65.0%-117.2%-136.7%-119.6%-75.2%-70.1%-68.2%

    Ratios